273 related articles for article (PubMed ID: 33193365)
1. Measurement of Cellular Immune Response to Viral Infection and Vaccination.
Bouwman W; Verhaegh W; Holtzer L; van de Stolpe A
Front Immunol; 2020; 11():575074. PubMed ID: 33193365
[TBL] [Abstract][Full Text] [Related]
2. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.
Liang H; Lee M; Jin X
Cell Mol Immunol; 2016 Jan; 13(1):36-46. PubMed ID: 26435066
[TBL] [Abstract][Full Text] [Related]
3. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles.
Gandini M; Reis SR; Torrentes-Carvalho A; Azeredo EL; Freire Mda S; Galler R; Kubelka CF
Mem Inst Oswaldo Cruz; 2011 Aug; 106(5):594-605. PubMed ID: 21894381
[TBL] [Abstract][Full Text] [Related]
4. Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.
Beeler JA; Eichelberger MC
Microb Pathog; 2013 Feb; 55():9-15. PubMed ID: 23247146
[TBL] [Abstract][Full Text] [Related]
5. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
Front Immunol; 2020; 11():577751. PubMed ID: 33133096
[No Abstract] [Full Text] [Related]
6. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
[TBL] [Abstract][Full Text] [Related]
8. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
9. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
10. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
[TBL] [Abstract][Full Text] [Related]
11. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
12. Intradermal vaccination to protect against yellow fever and influenza.
Roukens AH; Gelinck LB; Visser LG
Curr Top Microbiol Immunol; 2012; 351():159-79. PubMed ID: 21416266
[TBL] [Abstract][Full Text] [Related]
13. Vaccines licensed and in clinical trials for the prevention of dengue.
Torresi J; Ebert G; Pellegrini M
Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
[TBL] [Abstract][Full Text] [Related]
14. New vaccines against mucosal pathogens: rotavirus and respiratory syncytial virus.
Coffin SE; Offit PA
Adv Pediatr Infect Dis; 1997; 13():333-48. PubMed ID: 9544318
[No Abstract] [Full Text] [Related]
15. Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004).
Hadinegoro SR; Arredondo-García JL; Guy B; Bouckenooghe A; Noriega F; Jackson N
Vaccine; 2016 Aug; 34(36):4273-4. PubMed ID: 27452651
[No Abstract] [Full Text] [Related]
16. Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines.
Roberts NJ
Vaccine; 2019 Dec; 37(51):7451-7454. PubMed ID: 31607601
[TBL] [Abstract][Full Text] [Related]
17. Safety Follow-up of a Dengue Vaccine When Administered Concomitantly with a Yellow Fever Vaccine in Healthy Toddlers in Colombia.
Cortés M; López P; Márquez V; Cortes C; Toro E; Noriega F; Zambrano B
Pediatr Infect Dis J; 2018 Nov; 37(11):1190-1191. PubMed ID: 30308599
[TBL] [Abstract][Full Text] [Related]
18. Dengue and yellow fever--challenges for the development and use of vaccines.
Monath TP
N Engl J Med; 2007 Nov; 357(22):2222-5. PubMed ID: 18046026
[No Abstract] [Full Text] [Related]
19. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
[TBL] [Abstract][Full Text] [Related]
20. Sequential Infection with Common Pathogens Promotes Human-like Immune Gene Expression and Altered Vaccine Response.
Reese TA; Bi K; Kambal A; Filali-Mouhim A; Beura LK; Bürger MC; Pulendran B; Sekaly RP; Jameson SC; Masopust D; Haining WN; Virgin HW
Cell Host Microbe; 2016 May; 19(5):713-9. PubMed ID: 27107939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
